Clinical trials: Autotransplantation
Disorder of Endocrine Pancreas
Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy
The liver may not be an optimal site for islet transplantation due to obstacles by an instant blood-mediated inflammatory response, and low revascularization of transplanted islets.
- Trial name
- AUTOGRAFTIM (NCT02872571)
- Testing
- Intramuscular Islet Autograft
- Where
- 4 sites in France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Lille
Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer
Human Ovarian Autotransplantation
Chemotherapy can cause permanent damage to a woman's ovaries. Women who are cancer survivors may find that they are not able to produce female hormones, and they may not be able to have a child.
- Trial name
- NCT01403675
- Testing
- Ovarian autotransplantation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Samuel Kim, MD
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
Multiple Myeloma
Exploratory Study on POL6326 in Stem Cell Mobilization
The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation
- Trial name
- NCT01105403
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Polyphor Ltd.
Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
RATIONALE: The integrity of the intestinal mucosa is a key factor for the preservation of a normal gut function. Damage of the epithelium (i.e.
- Trial name
- NCT03417765
- Testing
- FE 203799
- Sponsor
- GlyPharma Therapeutics
Non-Hodgkin Lymphoma, Hodgkin Disease
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
- Trial name
- NCT00444912
- Testing
- G-CSF plus plerixafor, rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Sickle Cell Disease
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
- Trial name
- NCT06155500
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Burns, Skin Graft (Allograft)(Autograft) Failure
Prospective Randomized International Study on the Reactivation of Burn Injuries
This clinical trial will be a multi-centric prospective, randomized controlled study with the commercial objective of evaluating the clinical efficacy of a battery-powered portable device that uses blue LEDs.
- Trial name
- SPRINT (NCT04951934)
- Testing
- EmoLED, Standard treatment
- Where
- 6 sites in Austria, Italy
- Sponsor
- Emoled
Multiple Myeloma
Stem Cell Translpantation in Multiple Myeloma
The purpose of this study is to determine whether autologous transplantation (using the patient's own stem cells from the blood), followed by non-myeloablative (i.e.
- Trial name
- NCT05082675
- Testing
- HLA Matched allogeneic transplant
- Where
- 24 sites in Austria, Canada and 9 more
- Volunteers
- 357 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT03328936
- Testing
- Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Chronic Pancreatitis
Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Primary objective: To describe and compare the safety and efficacy of treatment with AAT in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation (TP-IAT).
- Trial name
- NCT02947087
- Testing
- Prolastin-C
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Medical University of South Carolina
Anterior Cruciate Ligament Injuries
The Use of Five-strand Hamstring Autograft to Increase the Graft Size in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Controlled Trial
Anterior cruciate ligament (ACL) reconstruction is one of most commonly performed orthopaedic surgeries. Several options for graft choice are available and autologous single bundle hamstring graft is most commonly used.
- Trial name
- NCT04531826
- Testing
- 5-strand hamstring graft preparation
- Volunteers
- 62 people
- Sponsor
- Hospital Authority, Hong Kong
Secondary Hyperparathyroidism;Parathyroidectomy
Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism
Total parathyroidectomy with autotransplantation (TPTX+AT) and Total parathyr- oidectomy alone (TPTX) are the common surgical procedures.The purpose of the study was to compare the long-term benefits of surgery between the two…
- Trial name
- NCT04922892
- Testing
- Parathyroidectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Myelopathy
Comparing Allograft to Autograft Bone in ACDF Surgeries
Anterior cervical discectomy and fusion (ACDF) is a surgery performed from the front of the neck in which damaged discs are removed and a bone graft is inserted into the space to allow the bone to grow together to set up a bridge…
- Trial name
- NCT03518164
- Testing
- Allograft
- Sponsor
- Rutgers, The State University of New Jersey
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Autologous Transplantation for Multiple Myeloma
The present study was designed in an attempt to prospectively evaluate in a randomized fashion whether further cytotoxic dose intensification, as delivered with two sequential autologous stem-cell transplantations, improved the…
- Trial name
- NCT00378222
- Testing
- Autologous Stem Cell Transplantation
- Volunteers
- 324 people
- Sponsor
- University of Bologna
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01330173
- Testing
- Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Submandibular Gland Stem Cell Transplantation
This study is a phase I safety and feasibility study to treat head and neck cancer patients with autologous salivary gland stem cell transplantation after postoperative (chemo)radiotherapy.
- Trial name
- RESTART (NCT04593589)
- Testing
- Submandibular Gland Stem Cell Transplantation
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
This clinical trial studies gene-modified, human immunodeficiency virus (HIV)-protected stem cell transplant in treating patients with HIV-associated lymphoma.
- Conditions
- AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma
- Trial name
- NCT02378922
- Testing
- Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center